查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671812

經皮貼片市場：市場機會、貼片劑量、定價、臨床試驗趨勢（2030年）

Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 300 Pages | 商品交期: 最快1-2個工作天內

價格

到2030年，全球經皮貼片市場價值預計將達到 180億美元。目前，美國佔據全球經皮貼片市場的主導地位，價值超過 40億美元。預計到2030年，中國將成為經皮貼片的成長市場。

全球經皮貼片市場正迅速轉變為一個充滿活力且競爭激烈的領域，新興公司和老牌公司都在不斷創新以滿足患者日益成長的需求。這些貼片有助於透過皮膚控制、穩定地釋放治療劑，以治療各種疾病，包括疼痛管理、戒菸和荷爾蒙替代療法。一個顯著的成功例子是尼古丁貼片，它在 21 世紀初作為一種戒菸輔助工具而廣受歡迎。從那時起，經皮貼片治療的疾病範圍大大擴展，現在包括治療注意力不足過動症、荷爾蒙缺乏症、噁心等。雖然經皮貼片往往比傳統藥物傳遞方法更昂貴，但其良好的安全性和有效性一直推動著市場成長。

監管部門的批准對於全球經皮貼片市場的擴張非常重要。獲得監管部門的批准對於確保經皮貼片作為藥物傳遞方法的可靠性非常重要。例如，Zydus Lifesciences 於2024年 8月獲得了 FDA 的最終批准，其東莨菪鹼經皮系統用於治療噁心和嘔吐。同樣，中國生物製藥於2024年 9月獲得 NMPA 批准，其利凡斯的明經皮貼片配方可用於治療輕度至中度阿茲海默症。此次核准是國產卡巴拉汀貼片首個在華獲批上市，更是經皮貼片在全球獲得認可的重要指標。

隨著藥物輸送系統的不斷創新，經皮貼片的商業可行性得到極大增強。例如，Anodyne Nanotech 的HeroPatch™ 平台已實現 GLP-1 受體促效劑（包括semaglutide）經皮給藥的生物利用度超過 50%，並已顯示出良好的臨床前結果。這項進步有可能替代傳統注射透過提供無針、每週一次的方法來改變糖尿病等慢性疾病的管理。 HERO Patch™ 的臨床試驗預計將於2025年開始，這將強化經皮貼片作為藥物傳遞技術關鍵組成部分的作用。

目前有幾種經皮貼片進行臨床試驗，凸顯了這種藥物傳遞方法的巨大潛力。這些貼片多個治療領域進行研究，包括慢性疼痛管理、糖尿病治療、甚至疫苗接種。目前全球已有近 70 種經皮貼片獲得核准，市場成長軌跡顯得強勁。仍存在一些挑戰，例如皮膚刺激和單一貼片輸送高劑量藥物的局限性，但研究人員在解決這些問題方面取得進展。經皮貼片的前景看好，藥物配方、貼片設計和患者依從性的持續改進預計將進一步推動市場成長。

本報告研究了全球經皮貼片市場，並概述了市場以及醫藥趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。

目錄

第1章 經皮貼片簡介

第2章 經皮貼片的分類

  • 黏合劑中的單層/多層藥物
  • 儲庫經皮貼劑
  • 基質為基礎的經皮貼片
  • 蒸氣貼片
  • 主動和被動貼片

第3章 經皮貼片的藥物傳遞機制

  • 經皮治療藥物的特點
  • 經皮貼片的成分
  • 暈動病機轉、尼古丁、女性經皮避孕貼片
  • 經皮貼片與傳統藥物傳遞方法的比較

第4章 全球經皮貼片市場前景

  • 當前市場狀況
  • 未來市場機會

第5章 依區域的全球透皮貼片市場趨勢

  • 美國
  • 歐洲
  • 中國
  • 日本
  • 韓國
  • 英國

第6章 依公司、適應症和階段全球貼片臨床新產品線

  • 研究
  • 臨床前
  • 第一階段
  • 第一/第二階段
  • 第二階段
  • 第三階段
  • 預先註冊
  • 已註冊

第7章 全球上市經皮貼片的臨床見解

第8章 心血管疾病經皮貼片 - 市場可用性、劑量與定價分析

  • Nitroglycerin經皮貼片
  • Clonidine經皮貼片
  • Bisoprolol經皮貼片（Bisono）

第9章 經皮止痛貼片 - 市場可用性、劑量與定價分析

  • Fentanyl經皮貼片
  • Buprenorphine經皮貼片
  • Diclofenac經皮貼片
  • Ketoprofen經皮貼片（Mohrus）
  • Lidocaine經皮貼劑
  • Capsaicin經皮貼片（Qutenza）
  • Methyl Salicate經皮貼片
  • Glycol Salicylate經皮貼片（Tokuhon E）
  • Flurbiprofen經皮貼劑

第10章 荷爾蒙治療中的經皮貼片－市場可用性、劑量與定價分析

  • 雌二醇經皮貼片
  • 睪固酮經皮貼片（Androderm）
  • 雌二醇/炔諾酮經皮貼劑
  • 雌二醇/左旋諾孕酮經皮貼劑
  • 乙炔雌二醇/左炔諾孕酮（Twirla）
  • 乙炔雌二醇/孕二烯酮（Apleek）

第11章 神經系統疾病中的經皮貼片－市場可用性、劑量與定價分析

  • Scopolamine經皮貼片（Transderm-Scop）
  • Selegiline經皮貼片（Emsam）
  • Methylphenidate經皮貼片（Daytrana）
  • Dextroamphetamine經皮貼片（Xelstrym）
  • Blonanserin經皮貼片（Lonasen）
  • Asenapine經皮貼片（Secuado）
  • Rivastigmine經皮貼劑
  • Rotigotine經皮貼片（Neupro）
  • Ropinirole Hydrochloride（Haruropi Tape）
  • Donepezil經皮貼片（Adlarity）

第12章 其他病症的貼片 - 市場供應、劑量與定價分析

  • Nicotine經皮貼片（Nicoderm CQ/Nicotinell TTS）
  • Oxybutynin經皮貼片（Oxytrol/Kentera）
  • Granisetron經皮貼片（Sancuso）
  • Emedastine經皮貼片（Allesaga）
  • Fibrin Sealant密封劑經皮貼劑
  • 5-Aminolevulinic Acid經皮貼片（Alacare）
  • Tulobuterol經皮貼劑

第13章 全球經皮貼片市場動態

第14章 競爭格局

  • AbbVie
  • Bayer HealthCare Pharmaceuticals
  • Corium International
  • Endo Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Luye Pharma
  • Noven Pharmaceuticals
  • Novartis
  • Purdue Pharma
  • Scilex Pharmaceuticals
  • Searchlight Pharma
  • Somerset Pharmaceuticals
  • Teikoku Seiyaku
  • Teva Pharmaceuticals
  • UCB
  • DURECT Corporation
  • Senju Pharmaceutical

Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030 Report Highlights & Findings:

  • Global Transdermal Patch Market Opportunity: US$ 18 Billion By 2030
  • US Currently Dominating Global Transdermal Patch Market: > US$ 4 Billion
  • China To Emerge Growing Market For Transdermal Patches By 2030
  • Currently More Than 60 Patches Are Approved Globally
  • Approved Patches Market Availability, Dosage & Price Analysis
  • Global Transdermal Market Insights By Region & Indications
  • Comprehensive Insight On Clinical Trials By Company, Indication & Phase
  • Competitive Landscape: Insight On Key Companies

The global market for transdermal patches has rapidly transformed into a dynamic and intensely competitive arena, where both emerging players and established firms are continually innovating to address the increasing demands of patients. These patches facilitate a controlled and consistent release of therapeutic agents through the skin, serving a diverse array of medical conditions, including pain management, smoking cessation, hormone replacement therapy, and more. An outstanding example of their success is the nicotine patch, which gained popularity as a smoking cessation aid in the early 2000s. Since then, the spectrum of conditions treated by transdermal patches has broadened considerably, now encompassing treatments for ADHD, hormone deficiencies, and nausea, among others. Although they tend to be pricier than conventional drug delivery methods, transdermal patches are witnessing consistent market growth, propelled by their advantageous safety and efficacy profiles.

An essential element in the ongoing expansion of the global transdermal patch market is the attainment of regulatory approval. Successful validations from regulatory authorities are crucial in affirming the credibility of transdermal patches as a viable drug delivery system. For example, Zydus Lifesciences received the final FDA approval for its scopolamine transdermal system aimed at treating nausea and vomiting in August 2024. Likewise, Sino Biopharmaceutical obtained NMPA approval in September 2024 for its rivastigmine transdermal patch, intended for the treatment of mild to moderate Alzheimer's disease. This approval represents a significant achievement, as it is the first domestically manufactured rivastigmine patch authorized for sale in China, emphasizing the increasing acceptance of transdermal patches on a global scale.

The commercial viability of transdermal patches is further enhanced significantly by ongoing innovations in drug delivery systems. For instance, Anodyne Nanotech's HeroPatch(TM) platform has demonstrated encouraging preclinical outcomes in the transdermal administration of GLP-1 receptor agonists, including semaglutide, achieving over 50% bioavailability. This advancement has the potential to transform the management of chronic diseases such as diabetes by providing a needle-free, weekly alternative to traditional injections. Clinical trials for the HeroPatch(TM) are anticipated to commence in 2025, reinforcing the role of transdermal patches as a pivotal element in drug delivery technology.

In another momentous development, researchers at Central South University in China have created a long-acting transdermal delivery system for Guanfacine, a non-stimulant medication for ADHD. This patch is designed to enhance drug release and ensure skin safety, with the capability of supporting treatment cycles lasting up to three days, thus offering a more convenient and patient-centric solution. Furthermore, Biotts, a Polish company specializing in drug delivery, is developing an insulin transdermal patch utilizing its MTC-Y carrier technology. This innovation allows for insulin delivery over a period of up to five days, providing a stable and extended alternative to the daily injections typically required by individuals with type 1 diabetes. Positive results from animal studies have been reported, and Biotts aims to begin human trials by 2027, which could significantly improve diabetes management for countless patients.

At present, there are multiple transdermal patches undergoing clinical trials, highlighting the significant potential of this method for drug delivery. These patches are being investigated across a growing array of therapeutic areas, such as chronic pain management, diabetes treatment, and even vaccination. With nearly 70 transdermal patches already receiving global approval, the market's growth trajectory appears strong, driven by technological advancements and an expanding spectrum of treatable conditions via transdermal means. Although challenges remain, including skin irritation and limitations in delivering higher drug dosages through a single patch, researchers are making progress in addressing these issues. The outlook for transdermal patches is promising, with ongoing enhancements in drug formulation, patch design, and patient adherence anticipated to further propel market growth.

In conclusion, transdermal patches are on the verge of becoming a widely accepted drug delivery method, providing considerable advantages in terms of patient convenience, reliable therapeutic delivery, and minimized side effects. As the market continues to grow, the clinical and commercial success of transdermal patches is expected to significantly influence the global pharmaceutical landscape, offering patients and healthcare providers more effective, less invasive, and more user-friendly alternatives to conventional drug delivery systems.

Table of Contents

1. Introduction To Transdermal Patch

  • 1.1 Overview Of Transdermal Patch
  • 1.2 Relevance Of Transdermal Patch

2. Transdermal Patches Classification

  • 2.1 Single/ Multiple Layer Drug In Adhesive
  • 2.2 Reservoir Transdermal Patches
  • 2.3 Matrix Based Transdermal Patches
  • 2.4 Vapor Patch
  • 2.5 Active & Passive Patch

3. Mechanism Of Transdermal Patch Drug Delivery

  • 3.1 Properties Of Transdermal Therapeutics
  • 3.2 Components Of Transdermal Patch
  • 3.3 Mechanism Of Motion Sickness, Nicotine & Female Contraceptive Transdermal

Patch

  • 3.4 Transdermal Patch v/s Traditional Drug Delivery Methods

4. Global Transdermal Patch Market Outlook

  • 4.1 Current Market Scenario
  • 4.2 Future Market Opportunity

5. Global Transdermal Patch Market Trends By Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 China
  • 5.4 Japan
  • 5.5 South Korea
  • 5.6 UK

6. Global Patch Clinical Pipeline By Company, Indication & Phase

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Phase-I
  • 6.4 Phase-I/II
  • 6.5 Phase-II
  • 6.6 Phase-III
  • 6.7 Preregistration
  • 6.8 Registered

7. Global Marketed Transdermal Patch Clinical Insight

8. Transdermal Patches For Cardiovascular Diseases - Market Availability, Dosage & Price Analysis

  • 8.1 Nitroglycerin Transdermal Patch
    • 8.1.1 Nitro-Dur
    • 8.1.2 Nitro TD Patch A
    • 8.1.3 Generic Nitroglycerin Transdermal Patch
  • 8.2 Clonidine Transdermal Patch
    • 8.2.1 Catapres-TTS
    • 8.2.2 Generic Clonidine Transdermal Patch
  • 8.3 Bisoprolol Transdermal Patch (Bisono)

9. Transdermal Analgesic Patches - Market Availability, Dosage & Price Analysis

  • 9.1 Fentanyl Transdermal Patch
    • 9.1.1 Duragesic/Durogesic
    • 9.1.2 Durotep MT
    • 9.1.3 OneDuro
    • 9.1.4 Generic Fentanyl Transdermal Patch
    • 9.1.5 Fentos
    • 9.1.6 Fentadur
    • 9.1.7 Generic Fentanyl Citrate Transdermal Patch
  • 9.2 Buprenorphine Transdermal Patch
    • 9.2.1 Butrans
    • 9.2.2 Bunov
    • 9.2.3 Sevodyne
    • 9.2.4 Transtec
    • 9.2.5 Generic Buprenorphine Transdermal Patch
  • 9.3 Diclofenac Transdermal Patch
    • 9.3.1 Zicthoru
    • 9.3.2 Flector
    • 9.3.3 Licart
  • 9.4 Ketoprofen Transdermal Patch (Mohrus)
  • 9.5 Lidocaine Transdermal Patch
    • 9.5.1 Versatis
    • 9.5.2 ZTlido
    • 9.5.3 Penles
    • 9.5.4 Rapydan
  • 9.6 Capsaicin Transdermal Patch (Qutenza)
  • 9.7 Methyl Salicate Transdermal Patch
    • 9.7.1 Salonpas
    • 9.7.2 Tokuhon
  • 9.8 Glycol Salicylate Transdermal Patch (Tokuhon E)
  • 9.9 Flurbiprofen Transdermal Patch
    • 9.9.1 Loqoa
    • 9.9.2 Yakuban Tape
    • 9.9.3 Transact Lat

10. Transdermal Patch In Hormonal Therapy - Market Availability, Dosage & Price Analysis

  • 10.1 Estradiol Transdermal Patch
    • 10.1.1 Alora
    • 10.1.2 Vivelle-Dot
    • 10.1.3 Minivelle
    • 10.1.4 Climara
    • 10.1.5 Menostar
    • 10.1.6 FemSeven
    • 10.1.7 Estrana
    • 10.1.8 Generic Estradiol Transdermal Patch
  • 10.2 Testosterone Transdermal Patch (Androderm)
  • 10.3 Estradiol/ Norethisterone Transdermal Patch
    • 10.3.1 Xulane/Ortho Evra
    • 10.3.2 Combipatch
    • 10.3.3 Menoaid Combi Patch
    • 10.3.4 Evorel Conti
  • 10.4 Estradiol/Levonorgestrel Transdermal Patch
  • 10.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
  • 10.6 Ethinyl Estradiol/Gestodene (Apleek)

11. Transdermal Patches For Neurological Disorders - Market Availability, Dosage & Price Analysis

  • 11.1 Scopolamine Transdermal Patch (Transderm-Scop)
  • 11.2 Selegiline Transdermal Patch (Emsam)
  • 11.3 Methylphenidate Transdermal Patch (Daytrana)
  • 11.4 Dextroamphetamine Transdermal Patch (Xelstrym)
  • 11.5 Blonanserin Transdermal Patch (Lonasen)
  • 11.6 Asenapine Transdermal Patch (Secuado)
  • 11.7 Rivastigmine Transdermal Patch
    • 11.7.1 Exelon
    • 11.7.2 Generic Rivastigmine Transdermal Patch
  • 11.8 Rotigotine Transdermal Patch (Neupro)
  • 11.9 Ropinirole Hydrochloride (Haruropi Tape)
  • 11.10 Donepezil Transdermal Patch (Adlarity)

12. Patches For Other Conditions - Market Availability, Dosage & Price Analysis

  • 12.1 Nicotine Transdermal Patch (Nicoderm CQ/ Nicotinell TTS)
  • 12.2 Oxybutynin Transdermal Patch (Oxytrol/Kentera)
  • 12.3 Granisetron Transdermal Patch (Sancuso)
  • 12.4 Emedastine Transdermal Patch (Allesaga)
  • 12.5 Fibrin Sealant Transdermal Patch
    • 12.5.1 Evarrest
    • 12.5.2 TachoSil
  • 12.6 5-Aminolevulinic Acid Transdermal Patch (Alacare)
  • 12.7 Tulobuterol Transdermal Patch
    • 12.7.1 Tulo-Touch
    • 12.7.2 Hokunarin

13. Global Transdermal Patch Market Dynamics

  • 13.1 Favorable Market Parameters
  • 13.2 Commercialization Challenges

14. Competitive Landscape

  • 14.1 AbbVie
  • 14.2 Bayer HealthCare Pharmaceuticals
  • 14.3 Corium International
  • 14.4 Endo Pharmaceuticals
  • 14.5 Hisamitsu Pharmaceutical
  • 14.6 Luye Pharma
  • 14.7 Noven Pharmaceuticals
  • 14.8 Novartis
  • 14.9 Purdue Pharma
  • 14.10 Scilex Pharmaceuticals
  • 14.11 Searchlight Pharma
  • 14.12 Somerset Pharmaceuticals
  • 14.13 Teikoku Seiyaku
  • 14.14 Teva Pharmaceuticals
  • 14.15 UCB
  • 14.16 DURECT Corporation
  • 14.17 Senju Pharmaceutical

List of Figures

  • Figure 1-1: Transdermal Permeation - Steps Involved
  • Figure 1-2: Transdermal Patch - Ideal Properties
  • Figure 2-1: Commercially Available Transdermal Patch Types
  • Figure 2-2: Multilayer Transdermal Patch
  • Figure 2-3: Reservoir Transdermal Patch System
  • Figure 2-4: Matrix Based Transdermal Patches
  • Figure 3-1: Transdermal Therapeutics - Properties
  • Figure 3-2: Transdermal Patch - Components
  • Figure 3-3: Permeation Enhancer - Types
  • Figure 3-4: Iontophoresis - Schematic Representation
  • Figure 3-5: Scopolamine Transdermal Patch - Mechanism
  • Figure 3-6: Nicotine Transdermal Patch - Mechanism
  • Figure 3-7: Female Contraceptive Transdermal Patch - Mechanism
  • Figure 3-8: Traditional Drug Delivery Methods - Challenges
  • Figure 3-9: Transdermal Patch - Advantages
  • Figure 3-10: Consistent Drug Supply By Transdermal Patch
  • Figure 4-1: Global - Transdermal Patch Market Size (US$ Billion), 2024 - 2030
  • Figure 4-2: Global Transdermal Patch Market By Region (US$ Billion), 2024
  • Figure 4-3: Global Transdermal Patch Market By Region (%), 2024
  • Figure 4-4: Global Transdermal Patch Market By Region (US$ Billion), 2030
  • Figure 4-5: Global Transdermal Patch Market By Region (%), 2030
  • Figure 8-1: Nitro-Dur - Price Per Unit & Supply Of Transdermal Films (US$), March'2025
  • Figure 8-2: Nitro TD Patch A - Price Per Unit & Supply Of Transdermal Films (US$), February'2025
  • Figure 8-3: Generic Nitroglycerin Transdermal Patch - Price Per Unit & Supply (US$), February'2025
  • Figure 8-4: Catapres-TTS - FDA Approval & First Generic Approval Year
  • Figure 8-5: Catapres-TTS - Price Per Unit & Supply (US$), February'2025
  • Figure 8-6: Catapres-TTS Transdermal Patch - Recommended Initial & Incremented Dose (mg/Week)
  • Figure 8-7: Generic Clonidine Transdermal Patch - Price Per Unit & Supply (US$), February'2025
  • Figure 8-8: Bisono - Approval Year By Indication
  • Figure 8-9: Bisono - Price Per Unit By Dose (US$), February'2025
  • Figure 8-10: Bisono - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 9-1: Duragesic - Approval Year By Region
  • Figure 9-2: Durotep MT - Price Per Unit By Dose (US$), February'2025
  • Figure 9-3: OneDuro - Price Per Unit By Dose (US$), February'2025
  • Figure 9-4: Generic Fentanyl Transdermal Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-5: Fentos - Price Per Unit By Dose (US$), February'2025
  • Figure 9-6: Fentos - Annual Sales (US$), 2020-2024
  • Figure 9-7: Generic Fentanyl Citrate Transdermal Patch - Price Per Unit By Dose (US$), February'2025
  • Figure 9-8: Butrans - FDA Approval Year By Dose
  • Figure 9-9: US - Butrans FDA Approval & 1st Generic Approval Year
  • Figure 9-10: Butrans - Approval Year By Region
  • Figure 9-11: Butrans - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-12: Butrans - Initial & Maximum Recommended Dose (mcg/hr)
  • Figure 9-13: Butrans - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 9-14: Bunov - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 9-15: Sevodyne - Price Per Supply (US$), February'2025
  • Figure 9-16: Transtec - Price Per Supply In UK (US$), February'2025
  • Figure 9-17: Generic Buprenorphine Transdermal Patch - Price Per Unit & Supply In US (USS), March'2025
  • Figure 9-18: Zicthoru - Price Per Unit & Supply (US$), February'2025
  • Figure 9-19: Zicthoru - Annual Sales (US$), 2021-2024
  • Figure 9-20: Branded & Generic Flector Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-21: Licart - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-22: Mohrus - Price Per Supply By Dose (US$), February'2025
  • Figure 9-23: Mohrus - Annual Sales (US$), 2020-2024
  • Figure 9-24: Versatis - Price Per Supply By Region (US$), February'2025
  • Figure 9-25: ZTlido - Price Per Unit & Supply (US$), February'2025
  • Figure 9-26: Qutenza - Price Per Unit By Region (US$), February'2025
  • Figure 9-27: Salonpas - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-28: Generic Methyl Salicylate Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-29: Tokuhon - Price Per Supply (US$), February'2025
  • Figure 9-30: Yakuban Tape - Price Per Supply Of 60mg Tape (US$), February'2025
  • Figure 9-31: Yakuban Tape - Price Per Supply Of 20mg Tape (US$), February'2025
  • Figure 9-32: TransAct Lat - Price Per Supply By Online Pharmacy (US$), February'2025
  • Figure 10-1: Alora - FDA Approval Year By Dose
  • Figure 10-2: Alora - Recommended Dose For Treatment Of Vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice In A Week)
  • Figure 10-3: Vivelle-Dot - FDA Approval & First Generic Approval Year
  • Figure 10-4: Vivelle-Dot - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-5: Vivelle-Dot - Recommended Dose (mg/Day Twice a Week)
  • Figure 10-6: Vivelle-Dot - Annual Sales (US$), 2020-2024
  • Figure 10-7: Minivelle - FDA Approval Year By Dose
  • Figure 10-8: Minivelle - FDA Approval & First Generic Approval Year
  • Figure 10-9: US - Minivelle Patent Issue & Expiration Year
  • Figure 10-10: Minnivelle - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-11: Minivelle - Recommended Dose By Indication (mg/Day)
  • Figure 10-12: Minivelle - Annual Sales (US$), 2020-2024
  • Figure 10-13: Climara - FDA Approval Year By Dose
  • Figure 10-14: Climara - FDA Approval & First Generic Approval Year
  • Figure 10-15: Climara - Price Per Unit & Supply In Canada (US$), February'2025
  • Figure 10-16: Menostar - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-17: FemSeven - Price Per Unit & Supply (Euro/US$), February'2025
  • Figure 10-18: FemSeven - Initial & Increased Dosage For Postmenopausal Symptoms (mg/hr)
  • Figure 10-19: Estrana - Price Per Supply (US$), February'2025
  • Figure 10-20: Estrana - Annual Sales (US$), 2020-2024
  • Figure 10-21: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Twice Weekly Patch In US (US$), March'2025
  • Figure 10-22: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Weekly Patch In US (US$), March'2025
  • Figure 10-23: Androderm - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-24: Androderm - Recommended Initial & Maintainence Dose For Treatment of Hypogonadism (mg/day)
  • Figure 10-25: Xulane - FDA Approval & First Generic Approval Year
  • Figure 10-26: Ortho Evara - FDA & EMA Approval Year
  • Figure 10-27: Xulane & Zafemy - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-28: Ethinyl Estradiol/Norelgestromin Patch - Recommended Schedule for Achieving Birth Control Effect (Days)
  • Figure 10-29: Evra - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 10-30: CombiPatch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-31: CombiPatch - Price Per Unit & Supply In Canada (US$), February'2025
  • Figure 10-32: CombiPatch - Annual Sales (US$), 2020-2024
  • Figure 10-33: Estradiol/Levonorgestrel - Approval Year By Region
  • Figure 10-34: Climara Pro - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-35: FemSeven Conti - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 10-36: US - Twirla Patent Issue & Expiration Year
  • Figure 10-37: Twirla - Price Per Unit & Supply (US$), March'2025
  • Figure 10-38: Twirla - Recommended Schedule For Achieving Birth Control Effect (Days)
  • Figure 11-1: Transderm-Scop - FDA Approval & 1st Generic Approval Year
  • Figure 11-2: Transderm-Scop - Price Per Unit & Supply (US$), March'2025
  • Figure 11-3: Scopolamine - Price Per Unit & Supply (US$), March'2025
  • Figure 11-4: Emsam - Price Per Unit & Supply (US$), March'2025
  • Figure 11-5: Daytrana - FDA Approval & Patent Exclusivity Year
  • Figure 11-6: US - Daytrana Patent Issue & Expiration Year
  • Figure 11-7: Daytrana - Price Per Unit & Supply (US$), March'2025
  • Figure 11-8: Daytrana - Annual Sales (US$), 2020-2024
  • Figure 11-9: Xelstrym - Price Per Unit & Supply (US$), March'2025
  • Figure 11-10: Xelstrym - Annual Sales (US$), 2023-2024
  • Figure 11-11: Lonasen - Price Per Unit in Japan (US$), February'2025
  • Figure 11-12: US - Secuado Patent Issue & Expiration Year
  • Figure 11-13: Secuado - Price Per Unit & Supply (US$), March'2025
  • Figure 11-14: Secuado - Recommended Initial & Incremented Dose (mg/Day)
  • Figure 11-15: Secuado - Annual Sales (US$), 2020-2024
  • Figure 11-16: Exelon - Approval Year By Region
  • Figure 11-17: US - Exelon FDA Approval Year & 1st Generic Approval Year
  • Figure 11-18: Exelon - Price Per Unit & Supply In US (US$), March'2025
  • Figure 11-19: Generic Rivastigmine Patch - Price Per Unit & Supply (US$), March'2025
  • Figure 11-20: Neupro - Approval Year By Region
  • Figure 11-21: US - Neupro Approval Year By Indication
  • Figure 11-22: Neupro - Patent Issue & Expiration Year
  • Figure 11-23: Neupro - Price Per Unit & Supply (US$), March'2025
  • Figure 11-24: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
  • Figure 11-25: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day)
  • Figure 11-26: Neupro - Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
  • Figure 11-27: Global - Neupro Sales (US$ Million), 2020-2024
  • Figure 11-28: Haruropi Tape Patch - Price Per Unit In Japan (US$), February'2025
  • Figure 11-29: Haruropi Tape - Initial & Maximum Recommended Dose (mg/day)
  • Figure 11-30: Haruropi - Annual Sales (US$), 2020-2024
  • Figure 11-31: Adlarity - Price Per Unit & Supply In US (US$), February'2025
  • Figure 12-1: Nicotine Transdermal Patch - Approval Year By Region
  • Figure 12-2: Nicoderm CQ - Price Per Unit & Supply (US$), March'2025
  • Figure 12-3: Generic Nicotine Patch - Price Per Unit & Supply Of 7mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-4: Generic Nicotine Patch - Price Per Unit & Supply Of 14mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-5: Generic Nicotine Patch - Price Per Unit & Supply Of 21mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-6: Nicoderm CQ - Recommended Dose & Treatment Schedule For Patients with Consumption More Than 10 Cigarette/Days (mg/day)
  • Figure 12-7: Oxybutynin Transdermal Patch - Approval Year By Region
  • Figure 12-8: Oxytrol - Price Per Unit & Supply In US (US$), March'2025
  • Figure 12-9: Kentera - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 12-10: Sancuso - Approval Year By Region
  • Figure 12-11: US - Sancuso Patent Issue & Expiration Year
  • Figure 12-12: Allesaga - Price Per Unit By Dose (US$), February'2025
  • Figure 12-13: Allesaga - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 12-14: Allesaga - Annual Sales (US$), 2020-2023
  • Figure 12-15: Tulo-Touch - Price Per Unit By Dose (US$), February'2025
  • Figure 12-16: Hokunalin - Price Per Unit By Dose (US$), February'2025
  • Figure 13-1: Global Transdermal Patch Market - Favorable Parameters
  • Figure 13-2: Global Transdermal Patch Market - Commercialization Challenges

List of Tables

  • Table 2-1: Active v/s Passive Transdermal Patch
  • Table 3-1: Transdermal Patches For Various Disease Indications
  • Table 9-1: Duragesic - Initial Dose Conversion From Other Opioids
  • Table 9-2: Butrans - Initial Dose Calculation Using Previous Opioid (Morphine) Dosage
  • Table 11-1: Daytrana - Dose Increment Pattern For Treatment Of ADHD